Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Using DIM and Calcium D-Glucarate to reduce finasteride side effects. Discussion includes dosage, brand, and product effectiveness.

David Barreto shared that a London-based research group is conducting a 12-month trial for a new nutraceutical treatment for pattern hair loss, designed with Dr. Carlos Puig. The trial aims to provide robust data, with results expected in 1-2 years, potentially representing a significant advancement since finasteride’s introduction in 1997.

AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.

PP405 shows promise in regenerating hair by activating dormant follicles. Other treatments like VDPHL01 and Breezula are also advancing, providing new hope for hair loss solutions.

PTD-DBM therapy for hair loss is being developed by Dr. Kang-Yell Choi, with human testing planned in South Korea. Some clinics in the U.S. offer PTD-DBM/valproic acid therapy, but it hasn't completed trials yet.

IGFBP‐rP1 shows potential for treating androgenic alopecia by influencing hair cycle transitions. Increasing IGF-1 levels may have similar effects to Minoxidil and 5-AR inhibitors in reducing hair loss.

Fibrin-based hydrogels support stem cells for hair follicle regeneration, showing promise for alopecia treatment. They enhance cell viability, maintain stemness, and induce hair growth without teratoma formation.

A peptide-based hair loss treatment, PP405, reportedly increased hair density by 62% in 90 days, but these claims are unverified and met with skepticism. Users compared PP405 to Minoxidil and Finasteride, expressing doubts about its effectiveness without more evidence.

Fibrin hydrogels, when combined with stem cells, can induce hair follicle regeneration and show potential for treating alopecia. The study demonstrated successful hair growth in mice without adverse effects.

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.

PP405 is a new hair loss treatment targeting dormant hair follicles, with ongoing trials. Some users consider stopping finasteride and minoxidil to join trials, while others doubt its effectiveness.

PP405 aims to reactivate hair follicle stem cells to promote hair growth, but its effectiveness is debated. Some users are skeptical, citing past failures of similar treatments and questioning the company's claims.

PP405 shows promise in activating dormant hair follicles and increasing hair counts but lacks detailed efficacy data compared to minoxidil and finasteride. Opinions are mixed, with some optimism and skepticism about its effectiveness.

The conversation discusses using a lipodermal solution for hair loss, with concerns about side effects from multiple active ingredients. Users mention experiences with minoxidil, finasteride, and dutasteride, noting side effects like brain fog and sexual issues.

Fibrin-based hydrogels support stem cells for hair follicle regeneration, showing promise for treating alopecia and wound healing. They enhance cell viability, maintain stemness, and promote hair and tissue regeneration without teratoma formation.

The conversation discusses potential hair loss treatments focusing on stimulating IGF-1 at the follicle level using growth-factor cocktails and engineered peptides, such as Acetyl Tetrapeptide-3, Copper Tripeptide-1, Oligopeptide-20, Thymosin-β4, and Palmitoyl Tetrapeptide-7. It suggests that device-assisted delivery methods like microneedling may enhance effectiveness.

Thicair is a product combining microneedling and subdural vitamins for hair loss, containing ingredients like Panax Ginseng Root Extract and Copper Tripeptide-1. Users are skeptical, with one calling it "quackery."

Creatine supplementation may increase DHT levels, potentially affecting hair loss. A study is examining this effect, with participants taking 5 grams of creatine daily for six months.

Excessive scalp sebum, worsened by DHT, can lead to inflammation and hair loss, with clascoterone mentioned as a treatment. Diet changes seem ineffective for scalp sebum, and treatments like minoxidil and finasteride are suggested.

The conversation discusses using hair follicle dermal papilla exosomes for hair loss treatment. It inquires about purchasing options for this treatment.

User switched from finasteride to combination dutasteride and finasteride for hair density improvement. They noticed less hair shedding and more youthful skin, with a reply suggesting less DHT could increase elastin in skin.

Dutasteride and finasteride can cause changes in physical appearance, like more feminine features and increased water retention. Users report side effects such as reduced libido, weight gain, and improved skin clarity, while some notice no significant changes.

High DHEA levels may contribute to hair loss by increasing DHT in hair follicles, potentially explaining why finasteride is ineffective for some. Treatments like high-dose dutasteride and RU58841 are suggested, but the underlying cause, such as adrenal issues, should be investigated.

PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.

Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.

The conversation humorously discusses hair regrowth using PP405, with jokes about side effects and secret hair transplants. The user claims no side effects except craving cheese.

Switching from powdered dutasteride to softgel significantly reduced DHT levels, suggesting softgels are more effective due to better bioavailability. Users discuss the ineffectiveness of compounded forms and emphasize the importance of proper formulation for absorption.

The conversation discusses a botanically derived treatment for androgenetic alopecia using ingredients like saw palmetto, green tea, and evening primrose, showing impressive results over 270 days. Concerns include the study's uncontrolled nature and potential product motivation, with suggestions to enhance absorption through derma rolling.

PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.

A user applied tretinoin to their scalp for hair loss and found brown particles in the cream. They are seeking information about these particles.